Stomach cancer | Guidance and guideline topic | NICE

3 new

and

0 updated

products since January 2017.

NICE Pathways - mapping our guidance

Technology appraisal guidance

Capecitabine for the treatment of advanced gastric cancer (TA191) July 2010
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326) November 2014
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209) November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86) October 2004
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378) January 2016
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179) September 2009
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208) November 2010

Interventional procedures guidance

Laparoscopic gastrectomy for cancer (IPG269) July 2008

Quality standards

Suspected cancer (QS124) June 2016

NICE Guidelines

Suspected cancer: recognition and referral (NG12) June 2015

In development

Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622 (GID-TAG360) TBC Technology appraisal guidance
Oesophago-gastric cancer (GID-CGWAVE0801) January 2018 NICE guidelines
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056] (GID-TA10089) November 2017 Technology appraisal guidance